{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:22:22Z","timestamp":1793409742396,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer Inc","award":["Pfizer Inc"],"award-info":[{"award-number":["Pfizer Inc"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>PF-06817024 is a humanized antibody against interleukin-33 that has the potential to inhibit type 2 inflammation. An exploratory analysis of the pharmacodynamics and clinical effects of single and repeat doses of PF-06817024 was assessed in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and patients with moderate-to-severe atopic dermatitis (AD), respectively, as part of a Phase 1, first-in-human study. Rhinosinusitis symptoms were improved, and nasal polyps were decreased in size following treatment with PF-06817024 in patients with CRSwNP. In patients with AD, PF-06817024, in aggregate, reduced disease severity and improved symptoms, as demonstrated by greater percentage decrease from baseline in Eczema Area and Severity Index (EASI) scores and reduced pruritus numerical rating scores, compared with placebo. The efficacy in AD appeared to be bimodal with a sub-group of participants exhibiting high levels of improvement (EASI75 and EASI90) for a sustained period of time after dosing. In patients with CRSwNP, a consistent trend of decrease in eosinophil levels was observed in the PF-06817024 group, compared with placebo. Further research would be needed to confirm the clinical benefit and safety of PF-06817024 as a treatment for allergic diseases.<\/jats:p><jats:p><jats:bold>Trial registration<\/jats:bold> ClinicalTrials.gov, NCT02743871. Registered 15 April 2016, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02743871?term=NCT02743871&amp;rank=1\">https:\/\/clinicaltrials.gov\/study\/NCT02743871?term=NCT02743871&amp;rank=1<\/jats:ext-link>.<\/jats:p>","DOI":"10.1186\/s13223-024-00894-8","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T13:02:38Z","timestamp":1725022958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploratory pharmacodynamics and efficacy of PF-06817024 in a Phase 1 study of patients with chronic rhinosinusitis and atopic dermatitis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0587-5274","authenticated-orcid":false,"given":"Spencer I.","family":"Danto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Tsamandouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padma","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Y.","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean S.","family":"Beebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"1","key":"894_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1939-4551-7-12","volume":"7","author":"R Pawankar","year":"2014","unstructured":"Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J. 2014;7(1):12.","journal-title":"World Allergy Organ J"},{"issue":"1","key":"894_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13223-021-00531-8","volume":"17","author":"A Sweeney","year":"2021","unstructured":"Sweeney A, Sampath V, Nadeau KC. Early intervention of atopic dermatitis as a preventive strategy for progression of food allergy. Allergy Asthma Clin Immunol. 2021;17(1):30.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"11","key":"894_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1080\/03007995.2020.1815682","volume":"36","author":"S Chen","year":"2020","unstructured":"Chen S, Zhou A, Emmanuel B, Thomas K, Guiang H. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36(11):1897\u2013911.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"894_CR4","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.jaci.2015.10.009","volume":"136","author":"WW Stevens","year":"2015","unstructured":"Stevens WW, Lee RJ, Schleimer RP, Cohen NA. Chronic rhinosinusitis pathogenesis. J Allergy Clin Immunol. 2015;136(6):1442\u201353.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"894_CR5","first-page":"253","volume":"10","author":"I Baiardini","year":"2022","unstructured":"Baiardini I, Paoletti G, Mariani A, Malvezzi L, Pirola F, Spriano G, et al. Nasal polyposis quality of life (NPQ): development and validation of the first specific quality of life questionnaire for chronic rhinosinusitis with nasal polyps. Healthc (Basel). 2022;10(2):253.","journal-title":"Healthc (Basel)"},{"issue":"10023","key":"894_CR6","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109\u201322.","journal-title":"Lancet"},{"issue":"4","key":"894_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417\u201328. e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"894_CR8","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284\u201393.","journal-title":"Allergy"},{"issue":"Suppl 2","key":"894_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13223-018-0281-6","volume":"14","author":"S Kapur","year":"2018","unstructured":"Kapur S, Watson W, Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):52.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"894_CR10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/bjd.17683","volume":"181","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. Br J Dermatol. 2019;181(3):554\u201365.","journal-title":"Br J Dermatol"},{"issue":"5","key":"894_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/DER.0000000000000401","volume":"29","author":"JC Li","year":"2018","unstructured":"Li JC, Fishbein A, Singam V, Patel KR, Zee PC, Attarian H, et al. Sleep disturbance and sleep-related impairment in adults with atopic dermatitis: a cross-sectional study. Dermatitis. 2018;29(5):270\u20137.","journal-title":"Dermatitis"},{"issue":"7","key":"894_CR12","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/all.14318","volume":"75","author":"CA Akdis","year":"2020","unstructured":"Akdis CA, Arkwright PD, Bruggen MC, Busse W, Gadina M, Guttman-Yassky E, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582\u2013605.","journal-title":"Allergy"},{"issue":"10","key":"894_CR13","doi-asserted-by":"publisher","first-page":"e3331","DOI":"10.1371\/journal.pone.0003331","volume":"3","author":"C Moussion","year":"2008","unstructured":"Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel \u2018alarmin\u2019? PLoS ONE. 2008;3(10):e3331.","journal-title":"PLoS ONE"},{"issue":"5","key":"894_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","volume":"23","author":"J Schmitz","year":"2005","unstructured":"Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479\u201390.","journal-title":"Immunity"},{"issue":"8","key":"894_CR15","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.imbio.2015.02.005","volume":"220","author":"L Vocca","year":"2015","unstructured":"Vocca L, Di Sano C, Uasuf CG, Sala A, Riccobono L, Gangemi S, et al. IL-33\/ST2 axis controls Th2\/IL-31 and Th17 immune response in allergic airway diseases. Immunobiology. 2015;220(8):954\u201363.","journal-title":"Immunobiology"},{"issue":"6","key":"894_CR16","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","volume":"130","author":"JK Gittler","year":"2012","unstructured":"Gittler JK, Shemer A, Suarez-Farinas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ, et al. Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344\u201354.","journal-title":"J Allergy Clin Immunol"},{"issue":"20","key":"894_CR17","first-page":"4501","volume":"21","author":"L Zhang","year":"2017","unstructured":"Zhang L, Jiang LL, Cao ZW. Interleukin-33 promotes the inflammatory reaction in chronic rhinosinusitis with nasal polyps by NF-\u03baB signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(20):4501\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"894_CR18","doi-asserted-by":"crossref","unstructured":"Danto SI, Tsamandouras N, Reddy P, Gilbert S, Mancuso J, Page K, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06817024 in healthy participants, participants with chronic rhinosinusitis with nasal polyps, and participants with atopic dermatitis: a phase 1, randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2024;64(5):529\u201343.","DOI":"10.1002\/jcph.2360"},{"issue":"4","key":"894_CR19","first-page":"183","volume":"31","author":"VJ Lund","year":"1993","unstructured":"Lund VJ, Mackay IS. Staging in rhinosinusitus. Rhinology. 1993;31(4):183\u20134.","journal-title":"Rhinology"},{"issue":"5 Suppl","key":"894_CR20","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.jaci.2006.09.005","volume":"118","author":"EO Meltzer","year":"2006","unstructured":"Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA, et al. Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol. 2006;118(5 Suppl):S17\u201361.","journal-title":"J Allergy Clin Immunol"},{"issue":"2 Pt 1","key":"894_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1288\/00005537-198402000-00004","volume":"94","author":"RL Doty","year":"1984","unstructured":"Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984;94(2 Pt 1):176\u20138.","journal-title":"Laryngoscope"},{"issue":"5","key":"894_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","volume":"34","author":"C Hopkins","year":"2009","unstructured":"Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34(5):447\u201354.","journal-title":"Clin Otolaryngol"},{"issue":"4","key":"894_CR23","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","volume":"14","author":"EF Juniper","year":"1999","unstructured":"Juniper EF, O\u2019Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902\u20137.","journal-title":"Eur Respir J"},{"key":"894_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coi.2014.09.004","volume":"31","author":"C Cayrol","year":"2014","unstructured":"Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014;31:31\u20137.","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"894_CR25","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.4049\/jimmunol.181.9.5981","volume":"181","author":"M Suzukawa","year":"2008","unstructured":"Suzukawa M, Iikura M, Koketsu R, Nagase H, Tamura C, Komiya A, et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol. 2008;181(9):5981\u20139.","journal-title":"J Immunol"},{"issue":"13","key":"894_CR26","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1084\/jem.20130351","volume":"210","author":"M Salimi","year":"2013","unstructured":"Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013;210(13):2939\u201350.","journal-title":"J Exp Med"},{"issue":"9","key":"894_CR27","doi-asserted-by":"publisher","first-page":"e0217807","DOI":"10.1371\/journal.pone.0217807","volume":"14","author":"EL Angulo","year":"2019","unstructured":"Angulo EL, McKernan EM, Fichtinger PS, Mathur SK. Comparison of IL-33 and IL-5 family mediated activation of human eosinophils. PLoS ONE. 2019;14(9):e0217807.","journal-title":"PLoS ONE"},{"issue":"2","key":"894_CR28","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/cts.13157","volume":"15","author":"MP Kosloski","year":"2022","unstructured":"Kosloski MP, Kalliolias GD, Xu CR, Harel S, Lai CH, Zheng W, et al. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: phase I first-in-human and first-in-patient trials. Clin Transl Sci. 2022;15(2):384\u201395.","journal-title":"Clin Transl Sci"},{"key":"894_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12931-016-0321-z","volume":"17","author":"BM Salter","year":"2016","unstructured":"Salter BM, Oliveria JP, Nusca G, Smith SG, Tworek D, Mitchell PD, et al. IL-25 and IL-33 induce type 2 inflammation in basophils from subjects with allergic asthma. Respir Res. 2016;17:5.","journal-title":"Respir Res"},{"issue":"6","key":"894_CR30","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S1074-7613(01)00243-6","volume":"15","author":"MM Fort","year":"2001","unstructured":"Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001;15(6):985\u201395.","journal-title":"Immunity"},{"issue":"6","key":"894_CR31","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jaci.2022.07.003","volume":"150","author":"AG Stanbery","year":"2022","unstructured":"Stanbery AG, Shuchi S, von Jakob M, Tait Wojno ED, Ziegler SF, TSLP. IL-33, and IL-25: not just for allergy and helminth infection. J Allergy Clin Immunol. 2022;150(6):1302\u201313.","journal-title":"J Allergy Clin Immunol"},{"issue":"515","key":"894_CR32","doi-asserted-by":"publisher","first-page":"eaax2945","DOI":"10.1126\/scitranslmed.aax2945","volume":"11","author":"YL Chen","year":"2019","unstructured":"Chen YL, Gutowska-Owsiak D, Hardman CS, Westmoreland M, MacKenzie T, Cifuentes L, et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Sci Transl Med. 2019;11(515):eaax2945.","journal-title":"Sci Transl Med"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-024-00894-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-024-00894-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-024-00894-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T13:04:37Z","timestamp":1725023077000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-024-00894-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["894"],"URL":"https:\/\/doi.org\/10.1186\/s13223-024-00894-8","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in compliance with the ethical principles derived from the Declaration of Helsinki and all International Council for Harmonisation Good Clinical Practice guidelines. The final protocol, any amendments, and informed consent documentations were approved by the Western Institutional Review Board and the UC Davis Office of Research: Institutional Review Board. Written informed consent to participate in the study was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of and hold stock in Pfizer Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}